Did You Know...
...that several people are credited with the invention of the flush toilet? Most people have heard of Thomas Crapper (1837-1910), the sanitary engineer who invented the valve-and-siphon arrangement that made the modern toilet possible. Another claimant to "the throne" was British inventor Alexander Cumming who patented a toilet in 1775. Then there's a nameless Minoan (a native of ancient Crete) who lived 4,000 years ago who supposedly was ahead of his time and created the first flush toilet!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110550 | HDAC inhibitors and hormone targeted drugs for the treatment of cancer The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormona... | 02/07/2012 |
| 8088385 | PFKB3 inhibitor for the treatment of a proliferative cancer A methods and compounds for inhibiting 6-phosphofructo-2-kinase /fructose-2,6-bisphosphatase 3 (PFKFB3) are described. Also described are methods of inhibiting cell proliferation, treating cancer, and screening compounds to determine their ability to inhibit PFKFB3.... | 01/03/2012 |
| 7666423 | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived ... | 02/23/2010 |
| 7429381 | Production and use of novel peptide-based agents for use with bi-specific antibodies The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antib... | 09/30/2008 |
| 7427400 | Methods of cancer diagnosis and therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 09/23/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7411046 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 08/12/2008 |
| 7407656 | PSCA: prostate stem cell antigen and uses thereof The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and an... | 08/05/2008 |
| 7399835 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 07/15/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7381407 | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In p... | 06/03/2008 |
| 7378237 | Development of method for screening physiologically active pyrrole imidazole derivative A method for screening the effect of a segment A (chemical species A) on a substance (for example, a cell) containing DNA or RNA by using artificial chemical species. Namely, a method of detecting or identifying the function of a chemical species A on a substance co... | 05/27/2008 |
| 7371379 | Dosages for treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody. | 05/13/2008 |
| 7361336 | Methods of cancer therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 04/22/2008 |
| 7348413 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 03/25/2008 |
| 7341721 | β-microglobulin (βm) and anti-βm binding agents as anti-cancer therapeutics The present invention describes the use of agents that interact with major histocompatibility complex (MHC) HLA class I molecules, such as β2-microglobulin, or antibodies that bind to β2-microglobulin, for the treatment and prevention of mult... | 03/11/2008 |
| 7314619 | Inducing apoptosis using anti-Apo-2 antibodies Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. ... | 01/01/2008 |
| 7288252 | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 10/30/2007 |
| 7276237 | Human Mob-5 (IL-24) receptors and uses thereof The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of... | 10/02/2007 |
| 7247302 | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis The present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an immunoglobulin or Ig fusion protein molecule to the subject, the immunoglobulin molecule having a variable re... | 07/24/2007 |
| 7227002 | Human antibodies that bind human 17-A1/EpCAM tumor antigen The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP... | 06/05/2007 |
| 7217796 | Neutralizing human anti-IGFR antibody The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing th... | 05/15/2007 |
| 7211562 | Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes ... | 05/01/2007 |
| 7211257 | Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF). ... | 05/01/2007 |
| 7153508 | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 12/26/2006 |
| 7147850 | Therapeutic binding agents against MUC-1 antigen and methods for their use The invention provides therapeutic compositions comprising binding agents that specifically bind to tumor-associated MUC-1 and reduce, reverse or prevent their effects in cancer. More particularly, the invention provides therapeutic compositions that comprise a bind... | 12/12/2006 |
| 7097846 | 35 kD tumor associated protein antigen: uses and methods of detection This invention provides the isolation and characterization of a tumor associated antigen which can be used for immunodiagnosis, immunoprognosis, and therapy of human cancer. The antigen is a protein molecule with a molecular weight of about 35 kD after reduction and... | 08/29/2006 |
| 7094404 | Method for treating malignancy and autoimmune disorders in humans using tac antibodies The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated an... | 08/22/2006 |
| 7064191 | Process for purifying antibody The present invention relates to a process for purifying an antibody having a desired property, which comprises using a substance having an affinity to a carbohydrate binding to the antibody; a medicament comprising, as an active ingredient, the antibody purified by... | 06/20/2006 |
| 7060272 | Death domain containing receptor-4 agonist antibodies and methods The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptid... | 06/13/2006 |
| 7041292 | Treating prostate cancer with anti-ErbB2 antibodies The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies. ... | 05/09/2006 |
| 7029677 | Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing o... | 04/18/2006 |
| 7014847 | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The method comprises suppressing or otherwise inhibiting t... | 03/21/2006 |
| 6974668 | Development of method for screening physiologically active pyrrole imidazole derivative A method for screening the effect of a segment A (chemical species A) on a substance (for example, a cell) containing DNA or RNA by using artificial chemical species. Namely, a method of detecting or identifying the function of a chemical species A on a substance co... | 12/13/2005 |
| RE38916 | APC Antibodies A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC i... | 12/06/2005 |
| 6949245 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... | 09/27/2005 |
| 6946129 | Recombinant anti-CD40 antibody and uses thereof The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiate... | 09/20/2005 |
| 6926896 | Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put t... | 08/09/2005 |
| 6893638 | Methods for treating b cell lymphoma using CD80-specific antibodies The present invention relates to methods for treating B cell lymphoma using CD80-specific antibodies. ... | 05/17/2005 |
| 6875432 | Reduced-viscosity concentrated protein formulations The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.... | 04/05/2005 |
